25 more drugs subject to Inflation Reduction Act rebates

HHS has added 25 drugs to its list of products eligible for Inflation Reduction Act rebates. 

As part of the Inflation Reduction Act, the federal government can levy fines against drug manufacturers who raise the cost of drugs covered by Medicare Part B higher than the rate of inflation. 

Some Medicare members will see lower coinsurance costs between $1 to $443 per dose for drugs subject to inflation rebates, according to CMS. 

In a June 2 news release, the agency listed 43 drugs subject to reduced copays for Medicare beneficiaries between July 1 and September 30.

The agency named 25 new drugs to the list, and 18 drugs subject to rebates in the first quarter of 2023 remain on the list for the second quarter. 

In April, HHS removed seven drugs from its initial list of drugs subject to rebates. A spokesperson told Becker's the agency's standard procedure is to publish average sale price files several weeks before the quarter in which they take effect so the public can review them, and correct files as needed. 

Here are the new drugs named to the list: 

1. Adcetris (Seagen and Takeda Pharmaceuticals) 
2. Aggrastat (Medicure) 
3. Blincyto (Amgen) 
4. Crysvita (Kyowa Kirin) 
5. Cuvitru (Takeda Pharmaceuticals) 
6. Enjaymo (Bioverativ Therapeutics)
7. Folotyn (Acrotech Biopharma) 
8. Gammagard S/D (Takeda Pharmaceuticals) 
9. Gammaplex (Bio Products Laboratory) 
10. Imlygic (Amgen) 
11. Infugem (Sun Pharmaceutical Industries) 
12. Kyprolis (Amgen) 
13. Lupron Depot-Ped (AbbVie) 
14. Mononine (CSL Behring) 
15. Nplate (Amgen) 
16. Oncaspar (Servier Pharmaceuticals) 
17. Panhematin (Recordati Rare Diseases) 
18. Prolia (Amgen) 
19. Synribo (Teva Pharmaceuticals) 
20. Tezspire (Amgen) 
21. Trogarzo (Theratechnologies) 
22. Vabomere (Melinta Therapeutics) 
23. Varizig (Saol Therapeutics) 
24. Vectibix (Amgen) 
25. Vivitrol (Alkermes) 

Drugs remaining from the first quarter: 

1. Abelcet (Leadiant Biosciences)
2. Akynzeo (Helsinn Therapeutics)
3. Atgam (Pfizer)
4. Aveed (Endo Pharmaceuticals)
5. Bicillin C-R (Pfizer)
6. Bicillin L-A (Pfizer)
7. Carnitor (Leadiant Biosciences)
8. Cytogam (Saol Therapeutics)
9. Flebogamma DIF (Grifols)
10. Fragmin (Pfizer)
11. Humira (AbbVie)
12. Leukine (Partner Therapeutics)
13.  Minocin (Hovione)
14.  Nipent (Pfizer)
15. Padcev (Agensys and Seagen)
16. Rybrevant (Johnson & Johnson)
17.  Signifor LAR (Recordati)
18.  Xiaflex (Endo International)

Removed 

1. Mircera (Roche)
2. Sylvant (EUSA Pharma)